I oppose the Food and Drug Administration's recent approval of the Alzheimer's drug, Aduhelm (aducanumab).
The clinical evidence supporting Aduhelm is extremely weak. Three members of the FDA's advisory committee resigned in protest, and two congressional committees are investigating how and why the FDA chose to approve this drug.
Because of the lack of evidence, the risk of serious harms, and the outrageous price, I say no to Aduhelm. Add my name to those who have already signed.
If I am a clinician, I will not prescribe this drug or recommend it to my patients.
If I am an Alzheimer's patient or family caregiver, I will not ask for Aduhelm or accept it if it is offered to me.
I call on my local hospital to say no to this drug. Aduhelm has not been proven to work, and its $56,000-a-year price tag will rob the nation of the resources we need to make real improvements in the lives of elders and their families.